Skip to main content
European Commission logo
français français
CORDIS - Résultats de la recherche de l’UE
CORDIS

bLadder cAncer URine cEll aNalysis

Objectif

Bladder cancer is the 4th most common cancer in men and the 7th in women, with 330,000- 380,000 new cases annually worldwide or more than 150,000 in Europe and is one of the most expensive cancers to manage. Bladder cancer incidence is strongly related to age, with the highest incidence rates being in older men and women. Cystoscopy/cystoscopic biopsy remains the current gold standard diagnostic and monitoring tool. This procedure is highly invasive and expensive - costing up to €1200 per test - and has been reported to miss in the region of 25% of all bladder tumours. As an adjunct to cystoscopy, urine cytology is routinely carried out globally but its deficiencies in terms of poor cancer detection (low sensitivity) are well recognised and reported.

The overall objective of the LAUREN project is to provide a commercial non-invasive in vitro diagnostic that will significantly reduce the management cost of caring for bladder cancer patients, whilst at the same time improving patient comfort and reducing morbidity associated with current invasive procedures. The specific diagnostic is based on the MCM2 + Immunofluorescence biomarker for bladder cancer cells found in urine.The scope of the project is to complete the final development, validation and regulatory activities required to prepare a novel the new diagnostic for the market.

The objectives of the project are to:
PO1 Clinically validate the biomarkers including the addition of Immuno Fluorescence
PO2 Complete development of and validate a single use cell collection device,
PO3 Validate the cell recognition software for regulatory acceptance
PO4 Validate the software of an automated slide analysis system.
PO5 Prepare a complete evidence package to support obtaining a CE Mark and FDA approval for commercialisation

Appel à propositions

H2020-SMEInst-2014-2015

Voir d’autres projets de cet appel

Sous appel

H2020-SMEINST-2-2014

Régime de financement

SME-2 - SME instrument phase 2

Coordinateur

CYTOSYSTEMS LIMITED
Contribution nette de l'UE
€ 3 135 925,00
Adresse
UNION PLAZA (6TH FLOOR), 1 UNION WYND
AB10 1DQ ABERDEEN
Royaume-Uni

Voir sur la carte

PME

L’entreprise s’est définie comme une PME (petite et moyenne entreprise) au moment de la signature de la convention de subvention.

Oui
Région
Scotland North Eastern Scotland Aberdeen City and Aberdeenshire
Type d’activité
Private for-profit entities (excluding Higher or Secondary Education Establishments)
Liens
Coût total
€ 3 135 925,00